Epigenetics Market to be Worth $5.47 Billion by 2030
Meticulous
Research®—a
leading global market research company, published a research report
titled, ‘Epigenetics Market by Offering (Kits,
Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin
Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology) End
User (Pharma, Academics, Hospitals) – Global Forecast to 2030.’
According
to this latest publication from Meticulous Research®,
the global epigenetics market is projected to reach $5.47 billion by 2030 at a
CAGR of 15.7%. The growth of this market is driven by the rising incidence of
chronic diseases due to growth in the aging population, the increasing
prevalence of cancer, rising pharmaceutical R&D expenditures, the
increasing focus on epigenetics in drug discovery & development, and the
declining costs of genome sequencing. However, the lack of skilled professionals
restrains the growth of this market.
The
growing applications of epigenetics in non-oncology diseases and government
initiatives supporting large-scale genomic sequencing projects are expected to
generate growth opportunities for the stakeholders in this market. However,
standardization concerns associated with epigenetics procedures and the limited
applications of epigenetics in toxicology are major challenges to market
growth.
Download
Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5628
Key
Players
The
key players operating in the global epigenetics market are Thermo Fisher
Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN
N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.),
Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc.
(U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif
(U.S.), and Zymo Research Corporation (U.S.).
Epigenetics
Market: Future Outlook
The
global epigenetics market is segmented by Offering [Kits & Reagents (Kits
& Assays, Antibodies, Proteins & Enzymes, and Other Reagents),
Services, Software], Method [ DNA Methylation (Bisulfite Conversion,
High-resolution Melt (HRM) Analysis, Immunoprecipitation, Other DNA Methylation
Methods), Histone Modification, RNA Modification, Polymerase Chain Reaction
(PCR), Chromatin Analysis, Sonication, and Other Methods], Application
[Oncology, Non-oncology], End User [Biotechnology & Pharmaceutical
Companies, Academic & Research Institutes, and Hospitals & Diagnostic
Laboratories]and Geography. The study also evaluates industry competitors and
analyzes their market share at global and regional levels.
Among
all the offerings studied in this report, in 2023,
the kits & reagents segment is expected to account for the largest share of
the epigenetics market. The kits & reagents segment is further segmented
into kits & assays, antibodies, proteins & enzymes, and other reagents.
In 2023, the kits & assays segment is expected to grow at the highest CAGR
during the forecast period. Kits & assays are bundled components such as
primers, antibodies, histones, controls, and proteins used to study epigenetics
through chromatin analysis, DNA methylation, histone modification, and mi-RNA
analysis, among other methods. They are available in panels, discs, cassettes,
and cartridges. The repetitive use of kits & assays and the emergence of
sequencing, mi-RNA, and real-time PCR technologies, which provide real-time
results with high accuracy and shorter turnaround times, enhancing research and
disease diagnosis drives the segment's growth.
Speak
to Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5628
Among
all the methods studied in this report, in
2023, the DNA methylation segment is expected to account for the largest share
of the market. DNA methylation is further segmented into bisulfite conversion,
high-resolution melt (HRM) analysis, immunoprecipitation, and other DNA
methylation methods. The high-melt resolution (HRM) analysis segment is
projected to grow at the highest CAGR during the forecast period.
High-resolution
melt (HRM) analysis is a qualitative analysis of a DNA fragment’s melt curve
following PCR amplification. It is considered a next-generation application of
amplicon melting analysis. These assays require a real-time PCR detection
system with thermal stability, sensitivity, and HRM-dedicated software.
Combining improved qPCR instrumentation and saturating DNA-binding dyes allows
for identifying small variations in nucleic acid sequences through the
controlled melting of double-stranded PCR amplicons. Such advanced PCR
instruments coupled with HRM-compatible software enable the rapid analysis of
the resulting data sets and the discrimination of DNA sequences based on their
composition, length, GC content, or strand complementarity, leading to the
segment's growth.
Among
all the applications studied in this report, in
2023, the oncology segment is expected to account for the largest share of the
market. This large segment share can be attributed to the high burden of cancer
globally, supportive initiatives by the government and organizations for
cancer, and advances in cancer research. Cancer can be genetic or adaptive
depending on lifestyle, genetic factors, and secondary disorders.
Cancer
is one of the leading causes of death globally. It is a prominent obstacle to
improving life expectancy in every country. The exact cause of cancer is
unknown in many types; hence, there is a high focus on cancer research to
develop products for cancer management. Epigenetics helps differentiate the
nuclear organization, DNA methylation, and histone modification patterns
between cancer and normal cells. Several changes in cancer cells, such as lower
histone post-translational modifications (methylation or acetylation), are
associated with poor outcomes in prostate, lung, and kidney cancers. It is
leading to the use of epigenetics in cancer diagnosis and treatment.
Among
all end users studied in this report, in
2023, the pharmaceutical and biotechnology companies segment is expected to
account for the largest share of the epigenetics market. The largest share of
this segment is attributed to the rising demand for research-related products,
the increasing incidence of chronic diseases, pharmaceutical &
biotechnology companies’ rising R&D expenditures, technological
advancements in epigenetics, and the introduction of new epigenetics products
for chronic and rare diseases.
Buy
Now: https://www.meticulousresearch.com/Checkout/14597335
Among
all regions studied in this report, Asia-Pacific
is expected to grow at the highest CAGR during the forecast period. The highest
CAGR of the region is attributed to government initiatives for genetic
diseases, growing cancer incidence, rising geriatric population, rapid rise in
the prevalence of chronic diseases, rising R&D spending, and increasing
healthcare expenditure.
This
research report analyzes major geographies and provides a comprehensive
analysis of North America (U.S. and Canada), Europe (Germany, France, U.K.,
Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and
the Rest of Asia-Pacific), Latin America, and the Middle East & Africa.
Key
questions answered in the report-
· Which
are the high-growth market segments in terms of offering, method, application,
end user, and regions/countries?
· What
was the historical market for epigenetic products across the globe?
· What
are the market forecasts and estimates for the period 2023–2030?
· What
are the major drivers, restraints, challenges, opportunities, and trends in the
global epigenetics market?
· Who
are the major players in the global epigenetics market?
· What
is the competitive landscape, and who are the market leaders in the global
epigenetics market?
· What
are the recent developments in the epigenetics market?
· What
are the different strategies adopted by the major players in the epigenetics
market?
· What
are the geographical trends and high-growth regions/countries?
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous
Market Research Pvt. Ltd. in 2013 as a private limited company under the
Companies Act, 1956. Since its incorporation, the company has become the
leading provider of premium market intelligence in North America, Europe,
Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values.
Since the inception, we have only thrived to research, analyze, and present the
critical market data with great attention to details. With the meticulous
primary and secondary research techniques, we have built strong capabilities in
data collection, interpretation, and analysis of data including qualitative and
quantitative research with the finest team of analysts. We design our
meticulously analyzed intelligent and value-driven syndicate market research
reports, custom studies, quick turnaround research, and consulting solutions to
address business challenges of sustainable growth.
Contact
Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment